Endocrinology, Vol 126, 1478-1484, Copyright © 1990 by Endocrine Society

ARTICLES

Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands

PA Phillips, JM Abrahams, JM Kelly, V Mooser, D Trinder and CI Johnston
University of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia.

Arginine vasopressin (AVP) acts on at least two receptor types, classified on the basis of their second messengers. The V1 receptor acts via mobilization of intracellular calcium through phosphatidylinositol hydrolysis and influences blood pressure and hepatic glycogenolysis. The V2 receptor acts via cAMP through activation of adenylate cyclase and causes antidiuresis. Previous studies of the different AVP receptors have been hampered by the use of nonselective radioligands, such as [3H]AVP (which binds to all types of V1 and V2 receptors, certain oxytocin receptors, and neurophysins) as well as the difficulty of measurement of second messengers. This paper describes the use of selective V1 and V2 radioligands with in vitro autoradiography to study V1 and V2 binding sites in rat tissues. [125I][1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid), 7-sarcosine] arginine vasopressin ([125I][d(CH2)5,Sarcosine7]AVP), a selective V1 antagonist radioligand, bound to regions of the brain, testis, superior cervical ganglion, liver, blood vessels, and renal medulla. Pharmacological characterization of [125I][d(CH2)5,Sarcosine7]AVP binding was consistent with that expected for binding to V1 receptors. There was no specific binding demonstrable to pituitary, renal glomeruli, gut, heart, spinal cord, ovary, adrenal medulla, or adrenal cortex. [3H]1-deamino [8-D-arginine] vasopressin [( 3H]DDAVP), a potent V2 receptor agonist radioligand, was used to study V2 receptors. Specific binding was only identified in the kidney consistent with the known distribution of antidiuretic V2 receptors on renal collecting tubules. No binding was demonstrated on endothelium or liver where DDAVP might influence clotting factor release, nor in the brain, spinal cord, sympathetic ganglia, heart or vascular smooth muscle, regions where DDAVP might cause vasodilatation. These studies demonstrate the use of these radioligands to study V1 and V2 receptors in a variety of tissues. Also, since these ligands are selective they are of particular use to study the different receptor subtypes in tissues where V1 and V2 receptors coexist, such as in the kidney.

This article has been cited by other articles:

				K. Mutig, A. Paliege, T. Kahl, T. Jons, W. Muller-Esterl, and S. Bachmann Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1166 - F1177. [Abstract] [Full Text] [PDF]

				Y. Izumi, Y. Nakayama, T. Mori, H. Miyazaki, H. Inoue, Y. Kohda, T. Inoue, H. Nonoguchi, and K. Tomita Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1418 - F1426. [Abstract] [Full Text] [PDF]

				K. Machida, S. Wakamatsu, Y. Izumi, T. Yosifovska, T. Matsuzaki, Y. Nakayama, Y. Kohda, T. Inoue, H. Saito, K. Tomita, et al. Downregulation of the V2 vasopressin receptor in dehydration: mechanisms and role of renal prostaglandin synthesis Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1274 - F1282. [Abstract] [Full Text] [PDF]

				M. Carmosino, H. L. Brooks, Q. Cai, L. S. Davis, S. Opalenik, C. Hao, and M. D. Breyer Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct Am J Physiol Renal Physiol, January 1, 2007; 292(1): F351 - F360. [Abstract] [Full Text] [PDF]

				M.-M. Trinh-Trang-Tan, F. Lasbennes, P . Gane, N. Roudier, P. Ripoche, J.-P. Cartron, and P. Bailly UT-B1 proteins in rat: tissue distribution and regulation by antidiuretic hormone in kidney Am J Physiol Renal Physiol, November 1, 2002; 283(5): F912 - F922. [Abstract] [Full Text] [PDF]

				O. Vagnes, J. J. Feng, B. M. Iversen, and W. J. Arendshorst Upregulation of V1 receptors in renal resistance vessels of rats developing genetic hypertension Am J Physiol Renal Physiol, June 1, 2000; 278(6): F940 - F948. [Abstract] [Full Text] [PDF]

				D. Mavroidis, B. C. Sun, and W. E. Pae Jr Bridge to transplantation: the Penn State experience Ann. Thorac. Surg., August 1, 1999; 68(2): 684 - 687. [Abstract] [Full Text] [PDF]

				B. C. Sun, K. A. Catanese, T. B. Spanier, M. R. Flannery, M. T. Gardocki, L. S. Marcus, H. R. Levin, E. A. Rose, and M. C. Oz 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience Ann. Thorac. Surg., August 1, 1999; 68(2): 688 - 694. [Abstract] [Full Text] [PDF]

				M. Burnatowska-Hledin, I. B. Lazdins, L. Listenberger, P. Zhao, A. Sharangpani, V. Folta, and B. Card VACM-1 receptor is specifically expressed in rabbit vascular endothelium and renal collecting tubule Am J Physiol Renal Physiol, February 1, 1999; 276(2): F199 - F209. [Abstract] [Full Text] [PDF]

				L. Gnessi, A. Fabbri, and G. Spera Gonadal Peptides as Mediators of Development and Functional Control of the Testis: An Integrated System with Hormones and Local Environment Endocr. Rev., August 1, 1997; 18(4): 541 - 609. [Abstract] [Full Text] [PDF]

				Y. Hirata, H. Hayakawa, M. Kakoki, A. Tojo, E. Suzuki, D. Nagata, K. Kimura, A. Goto, K. Kikuchi, T. Nagano, et al. Receptor Subtype for Vasopressin-Induced Release of Nitric Oxide From Rat Kidney Hypertension, January 1, 1997; 29(1): 58 - 64. [Abstract] [Full Text]